Aluminum antimony nickel silicon titanium vanadium oxide

Endpoint summary

Additional information

No toxicokinetic data are available for Aluminium silicate and titanium oxide matrix doted with vanadium, nickel, and antimony. Based on an expert judgement, the available data for physical-chemical properties and the available, relevant toxicity data of the substance were taken into account for assessing the toxicokinetic behaviour of Aluminium silicate and titanium oxide matrix doted with vanadium, nickel, and antimony:

The inorganic substance Aluminium silicate and titanium oxide matrix doted with vanadium, nickel, and antimony (molecular weight of 1220 - 12777 g/mol) is a solid powder, with the following particle size distribution: D10 = 46.66 µm, D50 = 71.34 µm, D90 = 104.6 µm (Stintz/Grace 2010, RL1). The substance is insoluble in water (measured water solubility: < 0.11 mg/l at 22 °C, pH 6.5 (Paulus/Grace 2010, RL2) and the density is 2.5346 g/cm3 at 20 °C (Paulus/Grace 2010, RL1).

Absorption

Oral:

In an acute oral toxicity study, rats were administered Aluminium silicate and titanium oxide matrix doted with vanadium, nickel, and antimony by gavage in a limit test according to OECD guideline 423 (Richeux, 2010, RL1). The LD50 was > 2000 mg/kg bw; no mortality, clinical signs of toxicity or gross pathological abnormalities were observed. As the water solubility of the substance is very low and no effects were observed after acute oral administration of the substance, it is expected that the solubility of the substance under physiological conditions is also very low. Thus, also taking into account the high molecular weight of the substance (>1220 g/mol), bioavailability of Aluminium silicate and titanium oxide matrix doted with vanadium, nickel, and antimony in the gastrointestinal tract can not be excluded, but is considered to be very low.

Inhalation:

Preliminary investigations aiming at creating a sufficiently respirable test atmosphere of Aluminium silicate and titanium oxide matrix doted with vanadium, nickel, and antimony demonstrated that the test material is not capable of forming respirable dust (Weniger, 2010, RL1). The dust generated in the various preliminary experiments contained a respirable fraction (1-4 µm) of only about 1% and therefore has an inherently low exposure potential to the alveolar region of the lung.

Based on this fact, it can be assumed that there is only negligible pulmonar uptake of Aluminium silicate and titanium oxide matrix doted with vanadium, nickel, and antimony.

Dermal:

As the molecular weight of the inorganic substance Aluminium silicate and titanium oxide matrix doted with vanadium, nickel, and antimony is 1220 – 12777 g/mol, the bioavailablity via the skin is considered to be negligible.

This assumption is supported by the results obtained from an acute dermal toxicity study: Rats were administered Aluminium silicate and titanium oxide matrix doted with vanadium, nickel, and antimony by the dermal route in a limit test according to OECD guideline 402 (Richeux, 2010, RL1). The LD50 was > 2000 mg/kg bw; no mortality, clinical signs of toxicity or gross pathological abnormalities were observed.

 

Metabolism

For the inorganic substance Aluminium silicate and titanium oxide matrix doted with vanadium, nickel, and antimony, no metabolic steps are expected to occur.

   

Excretion

After oral ingestion, the water insoluble aluminium silicate and titanium oxide matrix doted with vanadium, nickel, and antimony is expected to pass the gastrointestinal tract without any relevant bioavailablility and metabolic modifications and is assumed to be excreted via the faeces.

After inhalation of aluminium silicate and titanium oxide matrix doted with vanadium, nickel, and antimony, any inhaled material is assumed to segregate in the naso-pharyngeal region and will either be coughed out or swallowed.